Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryJapanJapan
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Adrenergic Receptor
    (1)
  • Akt
    (1)
  • Androgen Receptor
    (1)
  • Antibacterial
    (2)
  • Antifungal
    (1)
  • Antioxidant
    (1)
  • Apoptosis
    (2)
  • COX
    (2)
  • TNF
    (2)
  • Others
    (13)
Filter
Search Result
Results for "

arthritic

" in TargetMol Product Catalog
  • Inhibitor Products
    25
    TargetMol | Activity
  • Natural Products
    9
    TargetMol | inventory
  • Recombinant Protein
    4
    TargetMol | natural
  • Peptides Products
    3
    TargetMol | composition
Clozic
T1083922494-47-9In house
Clozic (ICI 55897) exhibits reversible anti-proliferative effects and can be used in studies about serving as a potential anti-arthritic agent.
  • $469
In Stock
Size
QTY
Lupeol
T2895545-47-1
Lupeol (Monogynol B) is a novel androgen receptor inhibitor with anti-inflammatory and antioxidant activity.
  • $30
In Stock
Size
QTY
TargetMol | Citations Cited
SKF-86002
T236772873-74-6
SKF-86002 is an effective inhibitor of p38 MAP kinase (IC50: 0.5-1 uM); inhibits LPS-induced IL-1 and TNF-α production in human monocytes (IC50: 1 μM).
  • $31
In Stock
Size
QTY
TargetMol | Inhibitor Sale
TargetMol | Citations Cited
Resolvin D3
T41059916888-47-6
Resolvin D3 (RvD3) is a dysregulated mediator originating from docosahexaenoic acid (DHA). It plays a crucial role in reducing arthritic inflammation.
  • $383
35 days
Size
QTY
TargetMol | Inhibitor Sale
Clematichinenoside AR
TN1507761425-93-8
Clematichinenoside AR exerts anti-inflammatory and immunosuppressive properties, it has anti-arthritic effects on PI3K/Akt signaling pathway and TNF-α± associated with collagen-induced arthritis.
  • $163
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Cryogenine
T3832710308-13-1
Cryogenine is an alkaloid originally isolated from H. salicifolia that has anti-inflammatory activity.1 It inhibits prostaglandin synthetase (IC50 = 424 μM). Cryogenine (100 mg/kg per day, p.o.) reduces paw edema and the mean arthritic index in a rat model of adjuvant-induced polyarthritis.2 |1. Lema, W.J., Blankenship, J.W., and Malone, M.H. Prostaglandin synthetase inhibition by alkaloids of Heimia salicifolia. J. Ethnopharmacol. 15(2), 161-167 (1986).|2. Kosersky, D.S., Brown, J.K., and Malone, M.H. Effects of cryogenine on adjuvant-induced arthritis and serum turbidity in rats. J. Pharm. Sci. 62(12), 1965-1971 (1973).
  • $383
35 days
Size
QTY
TargetMol | Inhibitor Sale
RC-3095 acetate
TP2153162666-31-1
RC-3095 acetate is an antagonist of bombesin/gastrin-releasing peptide receptor (GRPR). It exerts protective effects by reducing gastric oxidative injury in the arthritic mice.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
Luteolin-7-rutinoside
T1189520633-84-5
Luteolin-7-rutinoside has both antifungal activities and anti-arthritic, can result in a combination therapy for the treatment of fungal arthritis due to C. albicans infection.
  • $188
35 days
Size
QTY
TargetMol | Inhibitor Sale
Tiaprofenic acid
T456133005-95-7
Tiaprofenic acid (Acido tiaprofenico) is a non-steroidal anti-inflammatory drug used to treat pain, especially arthritic pain.
  • $40
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Kirenol
T4S194352659-56-0
1. Kirenol (Kirel) has anti-oxidant, anti-inflammatory, anti-allergic, and anti-arthritic activities. 2. Kirenol is effective against gram-positive bacteria. 3. Kirenol possesses antitumor action on human chronic myeloid leukemia K562 cells in vitro. 4. Kirenol is capable of promoting osteoblast differentiation in MC3T3-E1 cells through activation of the BMP and Wnt/β-catenin signaling pathways. 5. Kirenol treatment reduces pro-inflammatory cytokine secretion, increases anti-inflammatory cytokine production, inhibits cell proliferation and induces apoptosis of CII-specific lymphocytes in vitro.
  • $50
In Stock
Size
QTY
BMS-751324
T68266948842-66-8
BMS-751324, a p38α MAPK inhibitor, features a carbamyl-methyl linkage precursor with esters and phosphate functional groups from hydroxyphenylacetic acid (HPA). It effectively reduces foot swelling and suppresses LPS-induced TNFα production in an arthritic rat model.
  • $2,720
10-14 weeks
Size
QTY
Lonicerin
TN187725694-72-8
Lonicerin has antioxidant, anti-arthritic and antifungal activities, it can result in a combination therapy for the treatment of fungal arthritis due to C. albicans infection.
  • $80
In Stock
Size
QTY
3'-Sialyllactose
T7265535890-38-1
3'-Sialyllactose (3'-SL), a prebiotic with anti-inflammatory and anti-arthritic properties, plays a role in maintaining immune homeostasis. As a common carbohydrate with the lowest toxicity level, it is utilized in inflammation research.
  • $1,520
1-2 weeks
Size
QTY
PDE4-IN-6
T62969
PDE4-IN-6 is a safe, potent and moderately selective inhibitor of PDE4, acting on PDE4B (IC50: 0.125 μM) and PDE4D (IC50: 0.43 μM). PDE4-IN-6 is able to down-regulate TNF-α and IL-6 expression levels, exhibits anti-inflammatory and anti-arthritic effects, and has potent immunomodulatory activity. PDE4-IN-6 has potential for anti-rheumatoid arthritis studies.
  • $1,520
10-14 weeks
Size
QTY
Aurantiamide acetate
TJS221656121-42-7
Aurantiamide acetate (Asperglaucide) was isolated from the fermentation broth of Aspergillus penicilloides for the first time. Aurantiamide acetate is a selective and orally active cathepsin inhibitor. Aurantiamide acetate has anti-inflammatory activities and can be used for the study of inflammatory diseases[1][2].
  • $123
In Stock
Size
QTY
beta-Amyrin acetate
TN14381616-93-9
beta-Amyrin acetate inhibits HMG-CoA Reductase (HMGCR) and sEH activity with IC50 of 3.4 μM. beta-Amyrin acetate has anti-inflammatory, antifungal, antioxidant, and anti-hyperlipidemic activities.
  • $68
In Stock
Size
QTY
Suprofen
T668740828-46-4
Suprofen (Suprol) is an IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It inhibits prostaglandin synthesis and has been proposed as an anti-arthritic.
  • $35
In Stock
Size
QTY
Pristimerin
T4S10501258-84-0
1. Pristimerin (Celastrol methyl ester) has anticancer activity , treatment with Pristimerin may be a potential strategy for the suppression of hypoxia-induced metastasis through the reversal of hypoxia-induced stem cell characteristics and EMT in cancer cells. 2. Pristimerin down-regulates the expression of pro-inflammatory mediators through blocking of NF-κB activation by inhibiting interconnected ROS/IKK/NF-κB signaling pathways, can effectively inhibit both arthritic inflammation and cartilage and bone damage in the joints.
  • $33
In Stock
Size
QTY
IRAK4-IN-18
T62950
IRAK4-IN-18 is a potent inhibitor of interleukin 1 receptor-associated kinase 4 (IRAK4) (IC50: 15 nM). IRAK4-IN-18 inhibits LPS-induced IL23 production in THP and DC cells and blocks the development of arthritis in rats, a model of arthritis. IRAK4-IN-18 can be used to study arthritic diseases.
  • $1,520
10-14 weeks
Size
QTY
Rp-cAMPS sodium salt
T36679142439-94-9
Rp-cAMPS sodium salt, a cAMP analog, is a potent, competitive cAMP-induced activation of cAMP-dependent PKA I and II (Kis of 12.5 μM and 4.5 μM, respectively) antagonist. Rp-cAMPS sodium salt is resistant to hydrolysis by phosphodiesterases[1][2][3][4][5][6]. A membrane-permeable competitive cAMP antagonist (Rp-cAMPS) that blocks PKA activation by binding to the regulatory subunits without dissociating the kinase holoenzyme also inhibits synaptic plasticity but has no effect on normal synaptic transmission[2]. Rp-cAMPS (10 μM, 15 min) decreases the monosynaptic EPSCs evoked at the PB-CeLC and BLA-CeLC synapses in slices from arthritic rats but not in control neurons from normal animals. The inhibitory effect of Rp-cAMPS is significant compared to predrug (ACSF) control values obtained in the same neurons[2]. [1]. R J de Wit, et al. Inhibitory action of certain cyclophosphate derivatives of cAMP on cAMP-dependent protein kinases. Eur J Biochem. 1984 Jul 16;142(2):255-60. [2]. Rothermel JD, et al. A mechanistic and kinetic analysis of the interactions of the diastereoisomers of adenosine 3’,5’-(cyclic)phosphorothioate with purified cyclic AMP-dependent protein kinase. Biochem J. 1988 May 1;251(3):757-62.[3]. Fu Y, et al. PKA and ERK, but not PKC, in the amygdala contribute to pain-related synaptic plasticity and behavior. Mol Pain. 2008 Jul 16;4:26.[4]. Kuriyama S, et al. Isoproterenol inhibits rod outer segment phagocytosis by both cAMP-dependent and independent pathways. Invest Ophthalmol Vis Sci. 1995 Mar;36(3):730-6.[5]. Dostmann WR, et al. Probing the cyclic nucleotide binding sites of cAMP-dependent protein kinases I and II with analogs of adenosine 3’,5’-cyclic phosphorothioates. J Biol Chem. 1990 Jun 25;265(18):10484-91.[6]. Van Haastert PJ, et al. Competitive cAMP antagonists for cAMP-receptor proteins. J Biol Chem. 1984 Aug 25;259(16):10020-4.
  • $1,220
6-8 weeks
Size
QTY
Glaucine
T5S2059475-81-0
Glaucine has antitussive, antioxidative potential and antiviral activities, it may be an anti-arthritic agent, it can enhance LPS and zymosan-induced IL-10 production. Glaucine can inhibit the migration and invasion of human breast cancer cells by MMP-9 i
  • $42
In Stock
Size
QTY
TargetMol | Inhibitor Sale
IRAK4-IN-19
T63315
IRAK4-IN-19 is a potent inhibitor of interleukin 1 receptor-associated kinase 4 (IRAK4) (IC50: 4.3 nM).IRAK4-IN-19 inhibits LPS-induced IL23 production in THP and DC cells and suppresses the development of arthritis in arthritis model rats.IRAK4-IN-19 can be used to study arthritic diseases.
  • $1,520
10-14 weeks
Size
QTY
AHR-15010
T23681132031-90-4
AHR-15010 is a novel anti-arthritic agent.
  • $1,520
6-8 weeks
Size
QTY
RC-3095
TP1470138147-78-1
RC-3095, a selective GRPR antagonist, has been shown to have anti-inflammatory properties in different models of inflammation.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
RC-3095 TFA
TP17011217463-61-0
RC-3095 TFA (RC-3095 (TFA)) is a bombesin/gastrin-releasing peptide (BN/GRP) antagonist with potential anticancer activity.
  • $365
Backorder
Size
QTY
TargetMol | Inhibitor Sale